Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drink fix a complication of cancer surgery?

NCT ID NCT06820320

Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether taking iohexol by mouth can treat chylous ascites, a leak of lymphatic fluid that can happen after abdominal or pelvic cancer surgery. The study enrolled 42 patients who developed this condition after surgery. The goal was to see if oral iohexol could stop the fluid buildup quickly and safely, potentially offering a simpler alternative to more invasive treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iohexol (a contrast agent taken by mouth)
What this could lead to
If it works, this could offer a simple, non-surgical treatment for chylous ascites after cancer surgery, reducing the need for more invasive procedures.
What could go wrong
This is a small, early-phase trial with only 42 participants. The results may not apply to all patients, and the safety and effectiveness need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

42 people

The number who actually took part.

Started

Feb 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients between the ages of 18 and 75 years; * Patients underwent retroperitoneal or extended lymphadenectomy for abdominal or pelvic malignant tumors; * Patients diagnosisted with postoperative Chylous ascites. Chylous ascites were defined by the presence of non-infectious, milky, or creamy effluent in drainage tubes surpassing 200 mL daily, paired with triglyceride concentrations exceeding 110 mg/dL Exclusion Criteria: * Patients with severe cardiac, hepatic and renal insufficiency; * Patients with a history of iohexol allergy or allergy to contrast media; * Patients who have received other interventions; * Patients with severe intestinal obstruction or intestinal perforation; * Patients who are unable to comply with the requirements of the study or are unable to complete follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal malignant tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Abdominal Neoplasms cancer chylous ascites metastatic malignant neoplasm in the lymph nodes neoplasm Pelvic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal neoplasm Chylous ascites Extended lymphadenectomy Pelvic neoplasms Retroperitoneal lymph node metastasis Retroperitoneal lymphadenectomy

Contacts and locations

Locations

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.